Purdue Pharma seeks to appeal US ruling that overturned its opioid regulations

Vials of prescription pain reliever OxyContin, 40 mg tablets, manufactured by Purdue Pharma LD lie on a shelf at a local pharmacy in Provo, Utah, United States, April 25, 2017. REUTERS / George Frey

Register now for FREE and unlimited access to Reuters.com

Register

Dec.31 (Reuters) – Purdue Pharma is seeking an appeal to the 2nd United States Court of Appeals against a judge’s decision to undo its restructuring plan that would have sheltered its owners from liability in opioid-related civil cases, according to a late filing. Thusday.

The appeal came after U.S. bankruptcy judge Robert Drain in White Plains, New York, extended temporary protections until February 1 against opioid litigation for members of the Sackler family who own Purdue Pharma, giving Purdue and the Sacklers long enough to continue the appeal.

The ruling Purdue is seeking to appeal came on Dec. 16, when U.S. District Judge Colleen McMahon overturned Drain’s ruling that released the billionaire Sackler family from liability in civil litigation over opioids in exchange for a payment of $ 4.5 billion.

Register now for FREE and unlimited access to Reuters.com

Register

In the court ruling on the OxyContin manufacturer’s bankruptcy settlement, McMahon found that the bankruptcy court did not have the authority to grant discharge and asked the appeals court to determine whether such releases were legally acceptable.

Purdue argues in Thursday’s filing that the Bankruptcy Code allows non-consensual third party release in his case. He also indicates that the US trustee, who appealed for approval of the plan by Drain, does not object to his ability to appeal to Circuit 2.

Purdue filed for bankruptcy in September 2019 amid 3,000 lawsuits accusing the company and members of the Sackler family of contributing to a public health crisis that has claimed the lives of approximately 500,000 people since 1999.

Register now for FREE and unlimited access to Reuters.com

Register

Reporting by Krystal Hu in Toronto Editing by Matthew Lewis

Our Standards: Thomson Reuters Trust Principles.

Source link

About Leah Albert

Check Also

ENVERIC BIOSCIENCES, INC. : Other events, financial statements and exposures (form 8-K)

Article 8.01 Other events. During the previous thirty days, Enveric Biosciences, Inc., a Delaware company …